Editorial: Decernotinib: A Next-Generation Jakinib

Arthritis and Rheumatology

Volumn 68, Issue 1, 2016, Pages 31-34

  Gadina, Massimo ^a   Schwartz, Daniella M ^a   O'Shea, John J ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARICITINIB; C REACTIVE PROTEIN; CYTOKINE; DECERNOTINIB; METHOTREXATE; TOCILIZUMAB; TOFACITINIB; ANTIRHEUMATIC AGENT; FUSED HETEROCYCLIC RINGS; VALINE;

DISEASE ACTIVITY SCORE; ENZYME INHIBITION; HUMAN; HYPERLIPIDEMIA; LYMPHOCYTOPENIA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; ANALOGS AND DERIVATIVES; ARTHRITIS, RHEUMATOID; FEMALE; MALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; MALE; METHOTREXATE; VALINE;

EID: 84951971252     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39463     Document Type: Review

References (17)

1. Genovese MC, van Vollenhoven RF, Pacheco-Tena C, Zhang Y, Kinnman N., VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol 2016; 68: 46-55.
2. O'Shea JJ, Holland SM, Staudt LM., JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013; 368: 161-70.
3. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A., The JAK-STAT pathway: impact on human disease and therapeutic intervention. Ann Rev Med 2015; 66: 311-28.
4. Leonard WJ, O'Shea JJ., Jaks and STATs: biological implications. Ann Rev Immunol 1998; 16: 293-322.
5. Gadina M., Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol 2014; 26: 237-43.
6. Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, et al., Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015; 74: 333-40.
7. Mahajan S, Hogan JK, Shlyakhter D, Oh L, Salituro FG, Farmer L, et al., VX-509 (decernotinib) is a potent and selective Janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther 2015; 353: 405-14.
8. Farmer LJ, Ledeboer MW, Hoock T, Arnost MJ, Bethiel RS, Bennani YL, et al., Discovery of VX-509 (decernotinib): a potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases. J Med Chem 2015; 58: 7195-216.
9. Fleischmann RM, Damjanov NS, Kivitz AJ, Legedza A, Hoock T, Kinnman N., A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol 2015; 67: 334-43.
10. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al., American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
11. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al., Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
12. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al., Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370: 2377-86.
13. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al, on behalf of the ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-60.
14. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al., Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995; 377: 65-8.
15. Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, et al., Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 2015; 67: 616-25.
16. McInnes IB, Kim HY, Lee SH, Mandel D, Song YW, Connell CA, et al., Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis 2014; 73: 124-31.
17. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA., Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27: 647-59.